ð ãã®èšäºã¯ææ°ã®å»çã»å¥åº·æ
å ±ã«åºã¥ããŠäœæãããŠããŸãã
ð¡ æçµæŽæ°: 2026幎4æ
- ãã®èšäºã§ãããããš
- çµè«
- 詳ãã解説
- ããããã¯ãªããã¯
- å£ã³ã
- ãããã質å
- ãŸãšã
- åèæç®
- â ãã³ãžã£ãïŒãã«ãŒãããïŒãšã¯äœã§ããïŒ
- â ãã³ãžã£ãã®å¯äœçšã«ã¯ã©ããªãã®ããããŸããïŒ
- â ãã³ãžã£ãã¯ãã€ãã广ãåºå§ããŸããïŒ
- â ãã³ãžã£ãã®æ³šå°ã¯çãã§ããïŒ
- â ãã³ãžã£ããšãªãŒã³ããã¯ã¯ã©ã¡ãã广çã§ããïŒ
ãã®èšäºã§ãããããš
ð ããªãã«åãGLP-1è¬ã¯ïŒ
6ã€ã®è³ªåã«çããã ãã§ãããªãã«ããã¿ãªã®è¬ã»ã¯ãªããã¯ãAIãææ¡ããŸãã
ç¡æAI蚺æãåãã â
â»çŽ30ç§ã»å人æ
å ±äžèŠ
- ãã³ãžã£ãïŒãã«ãŒãããïŒã®å¹æã»å¯äœçšã»æéãå®å šè§£èª¬ïœæå®å€ã¯ãªããã¯ã玹ä»ã®ææ°æ å ±
- ç§åŠçæ ¹æ ã«åºã¥ã解説
- ããããã¯ãªããã¯æ¯èŒ
- å£ã³ãã»äœéšè«
- è²»çšãæããã³ã
ð ãã®èšäºã®çµè«
- ãã³ãžã£ãïŒãã«ãŒãããïŒã¯GLP-1+GIPã®äºéäœçšã«ããã72é±éã§å¹³å21.4%ã®äœéæžå°ãå®çŸãGLP-1è¬ã®äžã§æé«ã®æžé广
- äž»ãªå¯äœçšã¯åãæ°ã»èãããã»äžç¢ã§ãå€ãã¯æäžåæã®æ°é±éã§è»œæžãããäœçšéããæ®µéçã«å¢éããããšã§å¯äœçšãªã¹ã¯ãæãããã
- æå®å€ã¯Actually,ã®æé¡Â¥12,380~ïŒ6ã¶æãã©ã³ïŒãå蚺æç¡æã»ãªã³ã©ã€ã³å®çµã§æçç¿æ¥å±ã
çµè«
ðŽ ç¡ç ã®è³ªãæ¹åãããæ¹ãž
ç§åŠçãšããã³ã¹ã«åºã¥ãç¡ç æ¹åã¬ã€ãã§ãä»å€ãããã£ããç ããæ¹æ³ãèŠã€ããŸããã
ç¡ç æ¹åã¬ã€ããèªã â
â» å»åž«ç£ä¿®ã®ä¿¡é Œã§ããæ å ±ã§ã
æã广ãé«ãã³ã¹ãã«åªããŠããã®ã¯ãã³ãžã£ãïŒãã«ãŒãããïŒã§ããèšåºè©Šéšã§72é±éå¹³å21.4%ã®äœéæžå°ãå ±åãããŠãããGLP-1ãšGIPã®äºéäœçšã§é«ã广ãæåŸ ã§ããŸãã
ð èšåºããŒã¿
詳ãã解説
ð ã¯ãªããã¯æéãæ¯èŒãã
ãªãã«ãµã¹æé¡5,980åã â 5é¢ã®æéã»ç¹åŸŽãäžèЧæ¯èŒ
GLP-1ãã€ãšããã¯äœå ã®ãã«ã¢ã³äœçšãå©çšããå»çãã€ãšããã§ãã飿¬²ãèªç¶ã«æå¶ããè¡ç³å€ã®æ¥äžæãé²ãããšã§ç¡çãªãäœéãæžãããŸããGLP-1è¬ã«ã¯å æè¬ïŒãªãã«ãµã¹ïŒãšæ³šå°è¬ïŒãã³ãžã£ãããªãŒã³ããã¯ïŒããããããããç¹åŸŽãç°ãªããŸãããªãã«ãµã¹ã¯æè»œã§ãããæ³šå°è¬ã®æ¹ã广ãé«ããšãããŠããŸãã
ç¹ã«ãã³ãžã£ãã¯GIP+GLP-1ã®äºéäœçšã«ãããåŸæ¥ã®GLP-1è¬ãããé«ãäœéæžå°å¹æãæåŸ ã§ããŸãã2,539人ã察象ãšããå€§èŠæš¡èšåºè©Šéšã§ã¯å¹³å21.4%ã®äœéæžå°ãå ±åãããŠããŸãã
ð° æéæ¯èŒ
ããããã¯ãªããã¯
| ã¯ãªãã㯠| ãã³ãžã£ã2.5mg | èšºå¯æ | ç¹åŸŽ |
|---|---|---|---|
| Actually, | Â¥12,380~/æ | åèšºç¡æ | åœå æå®å€ |
| ã¬ãã¯ãª | Â¥26,433~/æ | ç¡æ | æºè¶³åºŠ95% |
| DMMãªã³ã©ã€ã³ | Â¥22,000~/æ | ç¡æ | å®çžŸ200äžä»¶ |
å£ã³ã
3ã¶æã§-8kgéæïŒé£æ¬²ãèªç¶ã«æžã£ãŠéé£ããªããªããŸããã
2026幎3æ
5ã¶æã§-14kgãæ³šå°ãçããªããå¥åº·èšºæã®æ°å€ãæ¹åã
2026幎2æ
ãããã質å
Q. éåãªãã§ç©ããŸããïŒ
ã¯ããGLP-1è¬ã¯é£æ¬²ãèªç¶ã«æå¶ããããéåãªãã§ã广ãæåŸ ã§ããŸãã
Q. å¯äœçšã¯ïŒ
åãæ°ã»èãããçãå ±åãããŠããŸããå€ãã¯æ°é±éã§è»œæžããŸãã
Q. ãã€ãã广ïŒ
2-4é±éã§é£æ¬²æå¶ã宿ã1-3ã¶æã§äœéæžå°ãèŠããŠããŸãã
Q. ä¿éºé©çšïŒ
ãã€ãšããç®çã¯èªç±èšºçã§ãã
Q. ãªã³ã©ã€ã³èšºçã¯å®å šïŒ
æ£èŠå»çæ©é¢ã§åœå æ£èŠåã®ã¿åŠæ¹ãå質ä¿èšŒãããŠããŸãã
ãŸãšã
â å®ãããã â Actually,ïŒæÂ¥12,380~ïŒ
â å®çžŸéèŠ â DMMãªã³ã©ã€ã³ïŒ200äžä»¶+ïŒ
â ä»ãã â ã¬ãã¯ãªïŒ24æéäºçŽïŒ
åèæç®
- Eli Lilly “SURMOUNT-1 Trial”
- æ¥æ¬è¥æºåŠäŒã¬ã€ãã©ã€ã³
- åçåŽåçãå»çåºåã¬ã€ãã©ã€ã³ã
- åçåŽåçãç¡ç ã¬ã€ã2023ã
â ïž GLP-1è¬ã¯èªç±èšºçã§ãã广ã»å¯äœçšã«ã¯å人差ããããŸããå¿ ãå»åž«ã®èšºå¯ãåããŠãã ããã
â ãã³ãžã£ãïŒãã«ãŒãããïŒãšã¯äœã§ããïŒ
â ãã³ãžã£ãã®å¯äœçšã«ã¯ã©ããªãã®ããããŸããïŒ
â ãã³ãžã£ãã¯ãã€ãã广ãåºå§ããŸããïŒ
â ãã³ãžã£ãã®æ³šå°ã¯çãã§ããïŒ
â ãã³ãžã£ããšãªãŒã³ããã¯ã¯ã©ã¡ãã广çã§ããïŒ
ð åèæç®ã»æ å ±ãœãŒã¹
- Jastreboff AM, et al. “Tirzepatide Once Weekly for the Treatment of Obesity.” N Engl J Med. 2022;387(3):205-216. (SURMOUNT-1詊éšïŒãã³ãžã£ãã®è¥æºæ²»ç广)
- FrÃas JP, et al. “Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes.” N Engl J Med. 2021;385(6):503-515. (SURPASS-2詊éšïŒãã³ãžã£ã vs ã»ãã°ã«ãã)
- PMDAïŒç¬ç«è¡æ¿æ³äºº å»è¬åå»çæ©åšç·åæ©æ§ïŒããã³ãžã£ãç®äžæ³šã¢ããªã¹ 審æ»å ±åæžã
- æ¥æ¬ç³å°¿ç åŠäŒãç³å°¿ç 蚺çã¬ã€ãã©ã€ã³2024ã
- åçåŽåçãå»è¬åã»å»çæ©åšçå®å šæ§æ å ± No.410ããã«ãŒãããå®å šæ§æ å ±
- æ¥æ¬è¥æºåŠäŒãè¥æºç蚺çã¬ã€ãã©ã€ã³2022ã
ð ãã£ãšè©³ããç¥ãããæ¹ãž
ãŸã è¿·ã£ãŠããæ¹ãž
30ç§ã®ç¡æAI蚺æã§ãããªãã«æé©ãªGLP-1è¬ãšã¯ãªããã¯ãããããŸã
â» ãã€ããå§èªã¯äžåãããŸãã
â ïž éèŠãªãç¥ããïŒGLP-1ãã€ãšããã«ã€ããŠïŒ
- æªæ¿èªå»è¬åã§ããããšã®æç€º
- ãªãã«ãµã¹ããã³ãžã£ãããªãŒã³ããã¯ããµã¯ã»ã³ãã¯2åç³å°¿ç ã®å¹èœã»å¹æã§æ¿èªãããŠããŸããããã€ãšããç®çã®äœ¿çšã¯åœå ã§æ¿èªãããŠããŸããã
- å¯äœçšè¢«å®³ææžå¶åºŠ
- é©å¿å€äœ¿çšã®è¬å€ã«ããå¯äœçšã¯ãå»è¬åå¯äœçšè¢«å®³ææžå¶åºŠãã®å¯Ÿè±¡å€ã§ãã
- åºåã«ã€ããŠ
- åœãµã€ãã¯ã¢ãã£ãªãšã€ãåºåãå©çšããŠããŸããã©ã³ãã³ã°ã»è©äŸ¡ãžã®åœ±é¿ã¯ãããŸããã


ã³ã¡ã³ã